The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I The KETO-CTA Study

JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009

II Subclinical AF – Anticoagulate or Not?

Anticoagulation in Subclinical AF May Offer Little Benefit

https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31

Treat AFib 'Diagnosed' by Smartwatch

https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp

JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437
NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/
Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843
American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/

III GLP1a for Treatment of Fatty Liver Disease

ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258

Features

CABG Still Superior to Stents Despite FAME 3 Endpoint Swap

https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net